Pérez de Aguado

Oct 19, 2024 | academic.oup.com | García de Quevedo |Diana Isabel |Juan Carlos |Pérez de Aguado

Immune checkpoint inhibitors (ICI) have become an essential part of the therapeutic arsenal against most solid tumors. Their widespread use has prompted the search of predictive biomarkers of efficacy, and understanding their potential interactions with other drugs has become essential to optimize their use in clinical practice.